Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone therapy. Unfortunately, prostate cancer can develop resistance to hormone therapy and continue to progress despite ongoing treatment. This stage is known as metastatic-castration-resistant prostate cancer (mCRPC). Scientists have discovered higher levels of a protein called EZH2 in certain cancers, particularly prostate cancer, which has...
Pfizer Patient Summaries
MEVPRO-2 Patient Summary – Metastatic Castration Resistant
Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone therapy. Unfortunately, prostate cancer can develop resistance to hormone therapy and continue to progress despite ongoing treatment. This stage is known as metastatic-castration-resistant prostate cancer (mCRPC). Scientists have discovered higher levels of a protein called EZH2 in certain cancers, particularly prostate cancer, which has...
